AAAAAA

   
Results: 1-12 |
Results: 12
CHANGES IN PSYCHOPHARMACOLOGICAL TREATMENT STRATEGIES IN SCHIZOPHRENIA - INPATIENT TREATMENT 1989 VS. 1995
Authors: KURZ M HAUSMANN A HONEDER M KEMMLER G KURZTHALER I WALCH T WECHDORN H FLEISCHHACKER WW
Citation: M. Kurz et al., CHANGES IN PSYCHOPHARMACOLOGICAL TREATMENT STRATEGIES IN SCHIZOPHRENIA - INPATIENT TREATMENT 1989 VS. 1995, Schizophrenia research, 29(1-2), 1998, pp. 155-156
VARIABLES INFLUENCING OUTPATIENTS COMPLIANCE
Authors: EDER U KOLLER D HUMMER M KURZTHALER I ULMER H FLEISCHHACKER WW
Citation: U. Eder et al., VARIABLES INFLUENCING OUTPATIENTS COMPLIANCE, Schizophrenia research, 29(1-2), 1998, pp. 161-161
LONG-TERM PHARMACOKINETICS OF CLOZAPINE
Authors: KURZ M HUMMER M KEMMLER G KURZTHALER I SARIA A FLEISCHHACKER WW
Citation: M. Kurz et al., LONG-TERM PHARMACOKINETICS OF CLOZAPINE, British Journal of Psychiatry, 173, 1998, pp. 341-344
RISK-FACTORS FOR THE DEVELOPMENT OF NEUROLEPTIC-INDUCED AKATHISIA
Authors: MILLER CH HUMMER M OBERBAUER H KURZTHALER I DECOL C FLEISCHHACKER WW
Citation: Ch. Miller et al., RISK-FACTORS FOR THE DEVELOPMENT OF NEUROLEPTIC-INDUCED AKATHISIA, European neuropsychopharmacology, 7(1), 1997, pp. 51-55
HEPATOTOXICITY OF CLOZAPINE
Authors: HUMMER M KURZ M KURZTHALER I OBERBAUER H MILLER C FLEISCHHACKER WW
Citation: M. Hummer et al., HEPATOTOXICITY OF CLOZAPINE, Journal of clinical psychopharmacology, 17(4), 1997, pp. 314-317
PROPRANOLOL TREATMENT OF OLANZAPINE-INDUCED AKATHISIA
Authors: KURZTHALER I HUMMER M KOHL C MILLER C FLEISCHHACKER WW
Citation: I. Kurzthaler et al., PROPRANOLOL TREATMENT OF OLANZAPINE-INDUCED AKATHISIA, The American journal of psychiatry, 154(9), 1997, pp. 1316-1316
TERMINATION OF CLOZAPINE TREATMENT
Authors: KURZ M HUMMER M OBERBAUER H KURZTHALER I FLEISCHHACKER WW
Citation: M. Kurz et al., TERMINATION OF CLOZAPINE TREATMENT, Schizophrenia research, 18(2-3), 1996, pp. 4-4
HEPATOTOXICITY OF CLOZAPINE
Authors: HUMMER M OBERBAUER H KURZ M KURZTHALER I SCHNEGG G FLEISCHHACKER WW
Citation: M. Hummer et al., HEPATOTOXICITY OF CLOZAPINE, Schizophrenia research, 18(2-3), 1996, pp. 7-7
WEIGHT-GAIN INDUCED BY CLOZAPINE
Authors: HUMMER M KEMMLER G KURZ M KURZTHALER I OBERBAUER H FLEISCHHACKER WW
Citation: M. Hummer et al., WEIGHT-GAIN INDUCED BY CLOZAPINE, European neuropsychopharmacology, 5(4), 1995, pp. 437-440
CLOZAPINE IN THE TREATMENT OF FIRST-EPISODE AND MULTI-EPISODE SCHIZOPHRENIC-PATIENTS
Authors: HUMMER M KURZ M KEMMLER J KURZTHALER I OBERBAUER H FLEISCHHACKER WW
Citation: M. Hummer et al., CLOZAPINE IN THE TREATMENT OF FIRST-EPISODE AND MULTI-EPISODE SCHIZOPHRENIC-PATIENTS, Schizophrenia research, 15(1-2), 1995, pp. 153-153
EFFICACY OF MEDIUM-DOSE CLOZAPINE FOR TREATMENT-RESISTANT SCHIZOPHRENIA
Authors: KURZ M HUMMER M KURZTHALER I OBERBAUER H FLEISCHHACKER WW
Citation: M. Kurz et al., EFFICACY OF MEDIUM-DOSE CLOZAPINE FOR TREATMENT-RESISTANT SCHIZOPHRENIA, The American journal of psychiatry, 152(11), 1995, pp. 1690-1691
CLOZAPINE DOSE IN THE UNITED-STATES AND EUROPE - IMPLICATIONS FOR THERAPEUTIC AND ADVERSE-EFFECTS
Authors: FLEISCHHACKER WW HUMMER M KURZ M KURZTHALER I LIEBERMAN JA POLLACK S SAFFERMAN AZ KANE JM
Citation: Ww. Fleischhacker et al., CLOZAPINE DOSE IN THE UNITED-STATES AND EUROPE - IMPLICATIONS FOR THERAPEUTIC AND ADVERSE-EFFECTS, The Journal of clinical psychiatry, 55(9), 1994, pp. 78-81
Risultati: 1-12 |